Neostigmine Administration after Spontaneous Recovery to a Train-of-Four Ratio of 0.9 to 1.0: A Randomized Controlled Trial of the Effect on Neuromuscular and Clinical Recovery

Anesthesiology

Volumn 128, Issue 1, 2018, Pages 27-37

  Murphy, Glenn S ^a   Szokol, Joseph W ^a   Avram, Michael J ^b   Greenberg, Steven B ^a   Shear, Torin D ^a   Deshur, Mark A ^a   Benson, Jessica ^a   Newmark, Rebecca L ^a   Maher, Colleen E ^a  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; FENTANYL; HYDROMORPHONE; NEOSTIGMINE; OXYGEN; PLACEBO; ROCURONIUM; SUXAMETHONIUM;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CONTROLLED STUDY; CORE TEMPERATURE; DIPLOPIA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; ELECTIVE SURGERY; ENDOTRACHEAL INTUBATION; EXTUBATION; FEMALE; HUMAN; HYPOXEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUSCLE STRENGTH; NAUSEA; NEUROMUSCULAR FUNCTION; NEUROMUSCULAR MONITORING; OXYGEN THERAPY; OXYGENATION; PARESIS; PATIENT MONITORING; PHARMACY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOVERY ROOM; AGED; ANESTHETIC RECOVERY; CONVALESCENCE; DRUG EFFECTS; MUSCLE RELAXATION; NEUROMUSCULAR JUNCTION; PHYSIOLOGY; PROCEDURES;

ADULT; AGED; ANESTHESIA RECOVERY PERIOD; CHOLINESTERASE INHIBITORS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE RELAXATION; NEOSTIGMINE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR MONITORING; RECOVERY OF FUNCTION;

EID: 85038009229     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000001893     Document Type: Article

References (40)

1. Lien CA: Neostigmine: How much is necessary for patients who receive a nondepolarizing neuromuscular blocking agent? ANESTHESIOLOGY 2010; 112:16-8
2. Fuchs-Buder T, Meistelman C: Monitoring of neuromuscular block and prevention of residual paralysis [in French]. Ann Fr Anesth Reanim 2009; 28(suppl 2):S46-50
3. Naguib M, Kopman AF, Lien CA, Hunter JM, Lopez A, Brull SJ: A survey of current management of neuromuscular block in the United States and Europe. Anesth Analg 2010; 111:110-9
4. Debaene B, Plaud B, Dilly MP, Donati F: Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. ANESTHESIOLOGY 2003; 98:1042-8
5. Kopman AF, Eikermann M: Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia 2009; 64(suppl 1):22-30
6. Baillard C, Gehan G, Reboul-Marty J, Larmignat P, Samama CM, Cupa M: Residual curarization in the recovery room after vecuronium. Br J Anaesth 2000; 84:394-5
7. Maybauer DM, Geldner G, Blobner M, Pühringer F, Hofmockel R, Rex C, Wulf HF, Eberhart L, Arndt C, Eikermann M: Incidence and duration of residual paralysis at the end of surgery after multiple administrations of cisatracurium and rocuronium. Anaesthesia 2007; 62:12-7
8. Pietraszewski P, Gaszy?ski T: Residual neuromuscular block in elderly patients after surgical procedures under general anaesthesia with rocuronium. Anaesthesiol Intensive Ther 2013; 45:77-81
9. Arbous MS, Meursing AE, van Kleef JW, de Lange JJ, Spoormans HH, Touw P, Werner FM, Grobbee DE: Impact of anesthesia management characteristics on severe morbidity and mortality. ANESTHESIOLOGY 2005; 102:257-68
10. Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM: Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia. ANESTHESIOLOGY 2016; 125:647-55
11. Miller RD, Ward TA: Monitoring and pharmacologic reversal of a nondepolarizing neuromuscular blockade should be routine. Anesth Analg 2010; 111:3-5
12. Viby-Mogensen J: Postoperative residual curarization and evidence-based anaesthesia. Br J Anaesth 2000; 84:301-3
13. Brull SJ, Murphy GS: Residual neuromuscular block: Lessons unlearned-Part II: Methods to reduce the risk of residual weakness. Anesth Analg 2010; 111:129-40
14. Payne JP, Hughes R, Al Azawi S: Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth 1980; 52:69-76
15. Goldhill DR, Wainwright AP, Stuart CS, Flynn PJ: Neostigmine after spontaneous recovery from neuromuscular blockade: Effect on depth of blockade monitored with train-of-four and tetanic stimuli. Anaesthesia 1989; 44:293-9
16. Grosse-Sundrup M, Henneman JP, Sandberg WS, Bateman BT, Uribe JV, Nguyen NT, Ehrenfeld JM, Martinez EA, Kurth T, Eikermann M: Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: Prospective propensity score matched cohort study. BMJ 2012; 345:e6329
17. Caldwell JE: Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. Anesth Analg 1995; 80:1168-74
18. de Paula Ramos E, Antônio MB, Ambiel CR, Correia-de-Sá P, Alves-Do-Prado W: Paradoxical neostigmine-induced TOFfade: On the role of presynaptic cholinergic and adenosine receptors. Eur J Pharmacol 2014; 723:389-96
19. Eikermann M, Fassbender P, Malhotra A, Takahashi M, Kubo S, Jordan AS, Gautam S, White DP, Chamberlin NL: Unwarranted administration of acetylcholinesterase inhibitors can impair genioglossus and diaphragm muscle function. ANESTHESIOLOGY 2007; 107:621-9
20. Eikermann M, Zaremba S, Malhotra A, Jordan AS, Rosow C, Chamberlin NL: Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth 2008; 101:344-9
21. Herbstreit F, Zigrahn D, Ochterbeck C, Peters J, Eikermann M: Neostigmine/glycopyrrolate administered after recovery from neuromuscular block increases upper airway collapsibility by decreasing genioglossus muscle activity in response to negative pharyngeal pressure. ANESTHESIOLOGY 2010; 113:1280-8
22. Sasaki N, Meyer MJ, Malviya SA, Stanislaus AB, MacDonald T, Doran ME, Igumenshcheva A, Hoang AH, Eikermann M: Effects of neostigmine reversal of nondepolarizing neuromuscular blocking agents on postoperative respiratory outcomes: A prospective study. ANESTHESIOLOGY 2014; 121:959-68
23. McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M: Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. ANESTHESIOLOGY 2015; 122:1201-13
24. Astley BA, Katz RL, Payne JP: Electrical and mechanical responses after neuromuscular blockade with vecuronium, and subsequent antagonism with neostigmine or edrophonium. Br J Anaesth 1987; 59:983-8
25. Choi ES, Oh AY, Seo KS, Hwang JW, Ryu JH, Koo BW, Kim BG: Optimum dose of neostigmine to reverse shallow neuromuscular blockade with rocuronium and cisatracurium. Anaesthesia 2016; 71:443-9
26. Song IA, Seo KS, Oh AY, No HJ, Hwang JW, Jeon YT, Park SH, Do SH: Timing of reversal with respect to three nerve stimulator end-points from cisatracurium-induced neuromuscular block. Anaesthesia 2015; 70:797-802
27. Fuchs-Buder T, Meistelman C, Alla F, Grandjean A, Wuthrich Y, Donati F: Antagonism of low degrees of atracuriuminduced neuromuscular blockade: Dose-effect relationship for neostigmine. ANESTHESIOLOGY 2010; 112:34-40
28. Fox MA, Keens SJ, Utting JE: Neostigmine in the antagonism of the action of atracurium. Br J Anaesth 1987; 59:468-72
29. Fuchs-Buder T, Claudius C, Skovgaard LT, Eriksson LI, Mirakhur RK, Viby-Mogensen J; 8th International Neuromuscular Meeting: Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: The Stockholm revision. Acta Anaesthesiol Scand 2007; 51:789-808
30. Fuchs-Buder T, Hofmockel R, Geldner G, Diefenbach C, Ulm K, Blobner M: The use of neuromuscular monitoring in Germany [in German]. Anaesthesist 2003; 52:522-6
31. Duvaldestin P, Cunin P, Plaud B, Maison P: French survey of neuromuscular relaxant use in anaesthetic practice in adults [in French]. Ann Fr Anesth Reanim 2008; 27:483-9
32. Videira RL, Vieira JE: What rules of thumb do clinicians use to decide whether to antagonize nondepolarizing neuromuscular blocking drugs? Anesth Analg 2011; 113:1192-6
33. Grayling M, Sweeney BP: Recovery from neuromuscular blockade: A survey of practice. Anaesthesia 2007; 62:806-9
34. Norton M, Xará D, Parente D, Barbosa M, Abelha FJ: Residual neuromuscular block as a risk factor for critical respiratory events in the post anesthesia care unit. Rev Esp Anestesiol Reanim 2013; 60:190-6
35. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS, Nisman M: Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. ANESTHESIOLOGY 2008; 109:389-98
36. Murphy GS, Szokol JW, Marymont JH, Greenberg SB, Avram MJ, Vender JS: Residual neuromuscular blockade and critical respiratory events in the postanesthesia care unit. Anesth Analg 2008; 107:130-7
37. Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear T, Vender JS, Gray J, Landry E: Postoperative residual neuromuscular blockade is associated with impaired clinical recovery. Anesth Analg 2013; 117:133-41
38. Kopman AF, Yee PS, Neuman GG: Relationship of the trainof-four fade ratio to clinical signs and symptoms of residual paralysis in awake volunteers. ANESTHESIOLOGY 1997; 86:765-71
39. Murphy GS, Szokol JW, Avram MJ, Greenberg SB, Shear TD, Vender JS, Parikh KN, Patel SS, Patel A: Residual neuromuscular block in the elderly: Incidence and clinical implications. ANESTHESIOLOGY 2015; 123:1322-36
40. Kirkegaard-Nielsen H, Helbo-Hansen HS, Lindholm P, Severinsen IK, Bülow K: Time to peak effect of neostigmine at antagonism of atracurium-or vecuronium-induced neuromuscular block. J Clin Anesth 1995; 7:635-9